Results 41 to 50 of about 13,526 (188)

Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies

Respiratory Medicine Case Reports, 2020
We describe a case of fulminant onset, rapidly progressive-interstitial lung disease (RP-ILD) with anti-ARS antibodies (anti-PL-7). The patient was successfully treated with nintedanib in addition to intensive immunosuppressive therapies, including ...
Toyoshi Yanagihara, Kunihiro Suzuki, Ayaka Egashira, Naruhiko Ogo, Tatsuma Asoh, Tsukasa Nara, Kensaku Takatsuki, Seiji Yoshizawa, Sy Giin Chong, Naoki Hamada, Takashige Maeyama   +10 more
doaj   +1 more source

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases [PDF]

, 2021
Background: In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with adverse events that were manageable for most patients.
Wijsenbeek, Marlies, Rosas, Ivan, Kolb, Martin, Stowasser, Susanne, Schmitz, Manuela, Schlenker-Herceg, R, Tomassetti, Sara, Otaola, Maria, Ivan Rosas, Wijsenbeek - Lourens, Marlies, Rosas, I, Rozsa Schlenker-Herceg, Vincent Cottin, Susanne Stowasser, Coeck, Carl, Richeldi, L, Carl Coeck, Sara Tomassetti, Otaola, M, Cottin, V, Kolb, M, Cottin, Vincent, Maria Otaola, Manuela Schmitz, Song, Jin Woo, Coeck, C, Schmitz, M, Luca Richeldi, Marlies Wijsenbeek, Tomassetti, S, Martin Kolb, Stowasser, S, Song, JW, Schlenker-Herceg, Rozsa, 송진우, Richeldi, Luca, INBUILD Trial Investigators   +36 more
core   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Cardiovascular safety of the tyrosine kinase inhibitor nintedanib

, 2021
The intracellular tyrosine kinase inhibitor nintedanib has shown great efficacy for the treatment of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. However, the incidence rate of myocardial infarction (MI) among participants in
Valentina Mercurio, Paolo Spallarossa, Carlo Gabriele Tocchetti, Italo Porto, Mercurio, Valentina, Ameri, Pietro, Giacomo Tini, Spallarossa, Paolo, Porto, Italo, Pietro Ameri, Tini, Giacomo, Tocchetti, Carlo Gabriele   +11 more
core   +2 more sources

Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity

Respiratory Research, 2017
Background Nintedanib, a tyrosine kinase inhibitor that is specific for platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and vascular endothelial growth factor receptors (VEGFR), has recently been approved for ...
Seidai Sato, Shintaro Shinohara, Shinya Hayashi, Shun Morizumi, Shuichi Abe, Hiroyasu Okazaki, Yanjuan Chen, Hisatsugu Goto, Yoshinori Aono, Hirohisa Ogawa, Kazuya Koyama, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara, Yasuhiko Nishioka   +15 more
doaj   +1 more source

Nintedanib for Idiopathic Pulmonary Fibrosis

, 2017
Objective: To review the pharmacology, safety, and efficacy of nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF). Methods: A literature search was conducted via PubMed using the MeSH term “idiopathic pulmonary fibrosis” combined with ...
Abisola Tepede, Dinesh Yogaratnam
core   +1 more source

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Outcomes in Progressive Pulmonary Fibrosis in Systemic Autoimmune Rheumatic Diseases: Real‐World Data From the ILD‐PRO Registry

Arthritis &Rheumatology, EarlyView.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease–associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J. Bracken, Jeremy M. Weber, Megan L. Neely, Aparna C. Swaminathan, Scott M. Palmer, Erin M. Wilfong, Ann D. Chauffe, Elizabeth R. Volkmann   +7 more
wiley   +1 more source

Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study

ERJ Open Research, 2023
Background Nintedanib slows lung function decline for patients with non-idiopathic pulmonary fibrosis progressive pulmonary fibrosis (PPF) in clinical trials, but the real-world safety and efficacy are not known.
Lavanya Raman, Iain Stewart, Shaney L. Barratt, Felix Chua, Nazia Chaudhuri, Anjali Crawshaw, Michael Gibbons, Charlotte Hogben, Rachel Hoyles, Vasilis Kouranos, Jennifer Martinovic, Sarah Mulholland, Katherine J. Myall, Marium Naqvi, Elisabetta A. Renzoni, Peter Saunders, Matthew Steward, Dharmic Suresh, Muhunthan Thillai, Athol U. Wells, Alex West, Jane A. Mitchell, Peter M. George   +22 more
doaj   +1 more source

Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy

iNew Medicine, EarlyView.
Therapeutic mechanism, clinical efficacy and future directions for nerandomilast in pulmonary fibrosis. ABSTRACT The recent Phase III FIBRONEER trials establish nerandomilast, a novel oral phosphodiesterase 4B (PDE4B) inhibitor, as an effective therapy for idiopathic and progressive pulmonary fibrosis. By elevating cyclic adenosine monophosphate (cAMP),
Qianwen Bai, Jia Deng, Hongquan Wang, Yao Yao, Tao Wang   +4 more
wiley   +1 more source